

20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW. WHO.INT

Tel. direct:

+41 22 791

Fax direct:

+41 22 791

E-mail:

In reply please

refer to:

roadmapaccess@who.int

Your reference:

Mr T. Balasubramaniam Geneva Representative

Knowledge Ecology International (KEI)

1 route de Morillons

CP 2100

1211 Genève 2

via email: thiru@keionline.org

15 August 2018

Dear Mr Balasubramaniam,

Thank you for your letter of 3 August 2018 and for your welcomed interest in the Roadmap on access to medicines and vaccines 2019-2023. Your feedback on and support for this important global health challenge is very much appreciated.

Universal health coverage is at the centre of my priorities and the need to expand access to safe, effective, quality and affordable essential medicines and vaccines for all is critical to meet this goal. Contributions from stakeholders on the work that the World Health Organization (WHO) is doing to address this priority is essential.

The decision WHA71(8), requested the WHO Secretariat to consult with Member States in the development of the roadmap. In line with this we are currently collecting inputs through an online survey and will seek further feedback at the Member State consultation in WHO headquarters, Geneva, from 10 to 11 September 2018.

In addition, comments from non-State actors (NSAs) in official relations with WHO on the Roadmap on access to medicines and vaccines 2019-2023 are welcome and an informal discussion with NSAs is planned for 10 September for this purpose. Non-State actors will then have the opportunity to make a three minute statement at the meeting or via Webex. Copies of statements that are provided to WHO, in advance of the meeting, could be shared with Member States for their consideration at the Member State consultation on 10 and 11 September.

Meanwhile, in the lead up to the consultation, please do not hesitate to contact the organizers directly for further details and/or information.

Yours sincerely,

Dr Tedros Adhanom Ghebreyesus

Director-General